RPE65 and Retinal dystrophy: Gene therapy in ophthalmology has garnered renewed interest in recent years since the 2017 FDA approval of voretigene neparvovec-rzyl (Luxturna), a subretinal gene therapy using the AAV2 virus vector to deliver human RPE65 cDNA in RPE65-associated retinal dystrophy [138].